UnitedHealth Group (UNH)
NYSEHealth CareHealthcare PlansSnapshot 2026-07-07
$428.28+2.46%
Close 2026-07-07 · 1-day change
Reading UNH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track UNH free→NYSEHealth CareHealthcare PlansSnapshot 2026-07-07
Reading UNH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track UNH free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a stable compounder in the healthcare sector. The current thesis state is intact, supported by strong recent financial performance and a consistent management approach.
The valuation is stretched compared to peers, indicating that the market has high expectations for UNH's performance. There is a slight expectations gap, suggesting that some positive outcomes are already factored into the current valuation.
Fundamentals are likely to remain strong, given the management's focus on raising earnings per share (EPS) guidance and exiting non-U.S. businesses. There is a low probability of missing earnings expectations, although recent history and industry trends warrant cautious observation.
The thesis hinges on the performance of sector bellwethers like CVS, ELV, and CI. If these companies continue to exceed earnings expectations, it could bolster UNH's performance. Conversely, any negative guidance from these peers could pose risks to UNH's outlook.
Overall, UNH's long-term thesis appears stable, supported by strong fundamentals and sector momentum. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'mixed'.
Yes, our read has strengthened. This improvement is driven by the latest earnings beat and a positive 2025 revenue outlook of $445.5 billion to $448.0 billion, which supports growth expectations. There are no current threats noted that would weaken this outlook.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Higher revenue growth shows strong demand and good management of healthcare services.
Confirms:Q2 2026 revenue reported above $111.7 billion.
Disproves:Q2 2026 revenue reported below $111.7 billion.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Confirming the EPS outlook shows strong performance and growth.
Confirms:Q2 adjusted earnings exceed $4.12 per share, supporting the raised outlook.
Disproves:Q2 adjusted earnings fall below $4.12 per share, raising concerns about growth.
Why it matters: A drop in sector growth could impact UNH's performance. It’s important to track sector health.
Confirms:Sector revenue growth drops below its median over the next quarter.
Disproves:Sector revenue growth remains stable or increases.
Why it matters: An increase in EPS guidance shows strong performance and investor trust.
Confirms:Management raises the EPS outlook for 2026 to greater than $17.35 in a future earnings report.
Disproves:Management keeps the EPS outlook at or below $17.35 without changes.
Why it matters: Meeting this revenue goal shows strong growth. It can help future earnings.
Confirms:Management reports 2025 revenue in the range of $445.5B to $448.0B.
Disproves:Revenue falls outside of the $445.5B to $448.0B range.
Why it matters: This deal helps UnitedHealth make healthcare better for consumers.
Confirms:The acquisition will close in late 2026 if there are no regulatory delays.
Disproves:The deal might have regulatory problems or be delayed beyond 2026.